fig14

Figure 14. (A) Schematic illustration of the preparation of supramolecular nanoprodrugsDOX@GP5$$ \supset $$Pro-NFA and their applications in overcoming cancer drug resistance; (B) Cell viability of HepG2 cells and HepG2/ADR cells treated with free DOX and DOX@GP5$$ \supset $$Pro-NFA, respectively. This figure is quoted with permission from Yang et al.^[177]; (C) Schematic illustration of the preparation of supramolecular nanoprodrugs DOX@GP5$$ \supset $$Pro-ANI and their applications in overcoming cancer drug resistance; (D) Cell viability of HepG2/ADR cells treated with free DOX and DOX@GP5$$ \supset $$Pro-ANI (^**P < 0.01). This figure is quoted with permission from Yang et al.^[180]. DOX: Doxorubicin; GP5: galactose-modified pillar[5]arene.